GoAI
Get started
Chaoju Eye Care Holdings Limited logo

Chaoju Eye Care Holdings Limited

2219.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$2.54

HK$0.00 · 0.00%

Aug 25, 4:08 PM HKT

2219.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, myopia prevention and control, dry eye syndrome, and oculoplastic, as well as optical products and services. The company also provides treatment for eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases, and pediatric eye diseases. In addition, it offers Amblyopia recovery services; and sells eyewear, equipment, and optical products. Chaoju Eye Care Holdings Limited was founded in 1988 and is headquartered in Beijing, China.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Bo Zhou Zhang
Listed since
Jul 7, 2021
Employees
2,590

Market position

52-week range

Current HK$2.54

Open
HK$2.54
Previous close
HK$2.54
Volume
0
0× average
Average volume
363.56K
Average daily volume
Market cap
1.76B HKD
Beta
0.58
Market reference 1
50-day average
HK$2.5485
-0.33% below average
200-day average
HK$2.6514
-4.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.46B CNY
P/E (TTM)
8.23×
P/B (TTM)
0.63×
P/S (TTM)
1.11×
EV / EBITDA
4.42×
Earnings yield
10.53%
Free cash flow yield
6.46%
Dividend yield
9.54%

Profitability & efficiency

Gross margin
42.19%
Operating margin
17.79%
Net margin
13.49%
Return on equity
7.63%
Return on assets
6.07%
Return on invested capital
6.25%

Financial health

Debt / equity
0.1×
Current ratio
4.37×
Altman Z-score
3.68
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49%36%23%10%Gross margin, FY2021: 44.97%Gross margin, FY2022: 43.91%Gross margin, FY2023: 45.35%Gross margin, FY2024: 43.49%Gross margin, FY2025: 42.19%Operating margin, FY2021: 24.07%Operating margin, FY2022: 21.41%Operating margin, FY2023: 22.14%Operating margin, FY2024: 17.58%Operating margin, FY2025: 17.79%Net margin, FY2021: 16.21%Net margin, FY2022: 18.96%Net margin, FY2023: 16.72%Net margin, FY2024: 13.88%Net margin, FY2025: 13.49%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 44.97%. Gross margin FY2022 43.91%. Gross margin FY2023 45.35%. Gross margin FY2024 43.49%. Gross margin FY2025 42.19%. Operating margin FY2021 24.07%. Operating margin FY2022 21.41%. Operating margin FY2023 22.14%. Operating margin FY2024 17.58%. Operating margin FY2025 17.79%. Net margin FY2021 16.21%. Net margin FY2022 18.96%. Net margin FY2023 16.72%. Net margin FY2024 13.88%. Net margin FY2025 13.49%.

Income trends

Revenue

1.36B CNY-3.21%

Operating income

242.06M CNY-2.04%

Net income

183.45M CNY-5.96%
Income trends across reported periods1.53B CNY1.03B CNY534.86M CNY37.38M CNYRevenue, FY2021: 997.79M CNYRevenue, FY2022: 990.04M CNYRevenue, FY2023: 1.37B CNYRevenue, FY2024: 1.41B CNYRevenue, FY2025: 1.36B CNYOperating income, FY2021: 240.17M CNYOperating income, FY2022: 212M CNYOperating income, FY2023: 303.28M CNYOperating income, FY2024: 247.09M CNYOperating income, FY2025: 242.06M CNYNet income, FY2021: 161.75M CNYNet income, FY2022: 187.75M CNYNet income, FY2023: 228.91M CNYNet income, FY2024: 195.08M CNYNet income, FY2025: 183.45M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 997.79M CNY. Revenue FY2022 990.04M CNY. Revenue FY2023 1.37B CNY. Revenue FY2024 1.41B CNY. Revenue FY2025 1.36B CNY. Operating income FY2021 240.17M CNY. Operating income FY2022 212M CNY. Operating income FY2023 303.28M CNY. Operating income FY2024 247.09M CNY. Operating income FY2025 242.06M CNY. Net income FY2021 161.75M CNY. Net income FY2022 187.75M CNY. Net income FY2023 228.91M CNY. Net income FY2024 195.08M CNY. Net income FY2025 183.45M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue1.36B CNY1.41B CNY1.37B CNY990.04M CNY997.79M CNY
Cost of goods sold786.46M CNY794.15M CNY748.37M CNY555.35M CNY549.11M CNY
Gross profit573.9M CNY611.3M CNY621.13M CNY434.7M CNY448.67M CNY
Selling, general, and administrative329.6M CNY362.06M CNY327.45M CNY223.32M CNY224.43M CNY
Operating expenses331.84M CNY364.21M CNY331.57M CNY218.95M CNY222.15M CNY
Interest income33.45M CNY39.58M CNY41.31M CNY22.97M CNY8.33M CNY
Interest expense12.22M CNY10.65M CNY12.22M CNY11.9M CNY10.54M CNY
Depreciation and amortization88.97M CNY88.28M CNY123.36M CNY55.87M CNY83.52M CNY
Operating income242.06M CNY247.09M CNY303.28M CNY212M CNY240.17M CNY
Net income183.45M CNY195.08M CNY228.91M CNY187.75M CNY161.75M CNY

Company facts updated Aug 25, 2026.

Earnings

Latest EPS result
0.11

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.270.20.140.07Q1 '23No estimateQ3 '23No estimateQ1 '24No estimateQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ1 '26No estimateQ3 '26Estimate
Q1 2023, reported Mar 28, 2023: actual 0.136, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 29, 2023: actual 0.227, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 0.126, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 0.215, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 0.086, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual 0.175, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual 0.111, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 28, 2026: actual —, estimate 0.175, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.87B1.31B755.63M197.25MQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26MetQ3 '26Estimate
Q1 2023, reported Mar 28, 2023: actual 232.06M HKD, estimate 1.34B HKD, surprise -82.65%, Miss. Q3 2023, reported Aug 29, 2023: actual 748.56M HKD, estimate 1.75B HKD, surprise -57.25%, Miss. Q1 2024, reported Mar 26, 2024: actual 749.1M HKD, estimate 1.75B HKD, surprise -57.12%, Miss. Q3 2024, reported Aug 29, 2024: actual 788.94M HKD, estimate 1.73B HKD, surprise -54.49%, Miss. Q1 2025, reported Mar 26, 2025: actual 713.99M HKD, estimate 1.67B HKD, surprise -57.13%, Miss. Q3 2025, reported Aug 29, 2025: actual 765.15M HKD, estimate 780.65M HKD, surprise -1.99%, Miss. Q1 2026, reported Mar 31, 2026: actual 736.59M HKD, estimate 736.59M HKD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 28, 2026: actual —, estimate 764.57M HKD, surprise —, Comparison unavailable.

2219.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$204.2

+3.29%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

+0.09%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$223.2

+0.81%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$52.20

+7.41%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.58

+1.67%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.1

+0.60%

ETFs holding 2219.HK

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
67.46K
Weight
0.01%
AUM
687.92M USD
Expense ratio
0.65%
Price / 1D
$72.84+1.56%

Continue in GoAI

Research 2219.HK

research.disclaimer